Recent advances in biosensors for neurodegenerative disease detection

Ganesh, Hashwin V. S.; Chow, Ari M.; Kerman, Kağan

doi:10.1016/j.trac.2016.02.012

Cited by 53 publications

(26 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results indicated that the electrochemistry of the primary copper site of Aβ(4-x) peptides differs strikingly from that of Aβ (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). The Cu(II)/(III) redox process characteristic for the N-terminal FRH sequence in Cu(II)-Aβ (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) or Cu(II)-Aβ(4-10) was irreversible due to the presence of tyrosine oxidized by Cu(III)-Aβ(4-x). Experiments carried out at 1:1.8 peptide to Cu(II) molar ratio confirmed that both Aβ (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) and Aβ(4-16) have a second tetragonal Cu(II) binding site prone to irreversible reduction to Cu(I).…”

Section: Discussionmentioning

confidence: 98%

“…The Cu(II)/(III) redox process characteristic for the N-terminal FRH sequence in Cu(II)-Aβ (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) or Cu(II)-Aβ(4-10) was irreversible due to the presence of tyrosine oxidized by Cu(III)-Aβ(4-x). Experiments carried out at 1:1.8 peptide to Cu(II) molar ratio confirmed that both Aβ (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) and Aβ(4-16) have a second tetragonal Cu(II) binding site prone to irreversible reduction to Cu(I). Moreover, Aβ(4-x) peptides bind one Cu(II) ion in a fashion preventing toxic Fenton reaction.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, irreversible Cu(II)/Cu(I) redox processes were remarked for complexes of both Aβ peptides at potentials less positive than 0.5 V. Consistent with the previously proposed low affinity binding at His13 and His14, 14,31,32 two small anodic peaks at ca. 0.0 V and 0.4 V were observed for Aβ (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) and Aβ(1-16) mixed with 1.8 Cu(II) equiv (see Figs. 2A-2B), together with just one return cathodic peak, evidencing an irreversible Cu(II)/Cu(I) conversion.…”

Section: Methodsmentioning

confidence: 96%

“…For all presented CV curves, the scan rate (v) was 100 mV/s or 20 mV/s. The solution was saturated with argon during the experiments at 25 • C. (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) and Aβ(4-16) peptides alone and coordinated with 0.9 equiv Cu(II) ions are shown in Fig. 1.…”

Section: Methodsmentioning

confidence: 99%

“…These results indicated that the Cu(II) geometry in the ATCUN site remained square-planar [Cu(II)/Cu(III)] in the case of Cu(II)-Aβ (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16), while the structure of the second binding site for both Cu(II)-Aβ peptides is tetragonal and susceptible to reorganization upon the Cu(II)/Cu(I) process. Aβ(4-16).-To understand the absence of reversibility of the Cu(II)/Cu(III) redox couple of Aβ(4-16), the peptide was C-truncated to contain only the FRH sequence covering the high affinity metal site.…”

Section: Comparison Of Redox Properties Of Cu(ii) Coordinated By Aβ(1mentioning

confidence: 99%

See 4 more Smart Citations

Tuning the Redox Properties of Copper(II) Complexes with Amyloid-β Peptides

Wiloch

Wawrzyniak

Ufnalska

et al. 2016

J. Electrochem. Soc.

View full text Add to dashboard Cite

Copper complexes of metal binding domains of synthesized amyloid-β peptides -Aβ(1-16) and N-truncated Aβ(4-16) containing a novel N-terminal FRH sequence, as well as its shorter mutants were characterized by cyclic voltammetry. The influence of the peptide sequence and peptide to copper molar ratio on the electrochemical properties of the obtained structures were studied and discussed. The reversibility of the studied redox processes in copper complexes with Aβ(4-x) derivatives was also investigated. The results indicate the crucial role of Tyr10 in the redox process of the Aβ(4-x) complex, including the removal of reversibility of the Cu(II)/Cu(III) redox couple.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

Section: Comparison Of Redox Properties Of Cu(ii) Coordinated By Aβ(1mentioning

confidence: 99%

See 3 more Smart Citations

Tuning the Redox Properties of Copper(II) Complexes with Amyloid-β Peptides

Wiloch

Wawrzyniak

Ufnalska

et al. 2016

J. Electrochem. Soc.

View full text Add to dashboard Cite

show abstract

Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Hanif

Muhammad

Niu

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Central nervous system (CNS) disorders feature the progressive and selective loss of normal brain functions. CNS disorders often include an irreversible physiological and anatomical loss of neurons that can lead to dysfunction in various parts of the brain and eventually death. Glioblastoma multiforme (GBM) and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are hard to be diagnosed at an early stage for the prevention of disease propagation. Such diagnosis is vital for the timely commencement of actual treatments. Nanotechnology brings new diagnosis hope for CNS disorders as it provides ultrasensitive detection for more specific biomarkers. Herein, the recent progress in techniques development for detecting pathological biomarkers for GBM, AD, and PD is summarized, in particular, the principles that govern the design of these sensors, blood–brain barrier (BBB) dysfunction, and its integrity during disease development. Finally, a perspective on future directions to further advance and improve the early‐stage diagnosis of CNS disorders is presented.

show abstract

Recent Progress on Biosensors for the Early Detection of Neurological Disorders.

Chougale

Vedante

Kulkarni³

et al. 2022

ChemistrySelect

View full text Add to dashboard Cite

Neurological disorders are a point of attraction these days due to their physical, mental, and genetic threat to human beings. The researchers are refining the therapeutics and striving to eradicate the life-threatening burden of chronic diseases by upsurging and proposing advanced instrumentation. There are a number of neurological diseases that cause alterations in the genetic sequences due to pathogenic or self-negligence. According to the WHO, stroke, septicemia, PD, epilepsy, and MS are found to be the deadliest and most invading among millions of people. Various diagnostic methods are employed for monitoring these disorders in the human body at an early stage, in process of cure. The current review highlights the strengths of several advanced detection devices, such as biosensors to identify and quantify biomarkers, some sensing gadgets, and other genetic tactics or innovations to ameliorate traditional protocols. Furthermore, the meticulous description of ongoing experiments with the help of relevant case studies of neurodegenerative disorders supports the impact and vitality of advanced equipment. Further, the necessity of biosensors in distinct disorders to aid in an early diagnosis, and the influence of nano-based materials in preparation is emphasized. Finally, several issues that should be addressed in upcoming decades with the steep rise in analytical technology have been discussed.

show abstract

Recent advances in biosensors for neurodegenerative disease detection

Cited by 53 publications

References 71 publications

Tuning the Redox Properties of Copper(II) Complexes with Amyloid-β Peptides

Tuning the Redox Properties of Copper(II) Complexes with Amyloid-β Peptides

Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Recent Progress on Biosensors for the Early Detection of Neurological Disorders.

Contact Info

Product

Resources

About